Everything below concerns Translational gap. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
=== Noncovalent interactions === As mentioned above, aqueous chitosan has many positively charged amine groups. This makes it readily bind to negatively charged surfaces such as mucosal membranes. Chitosan can also effectively bind to other surface via hydrophobic interaction and/or cation-π interaction (chitosan as a cation source) in aqueous solution.
dihydrothymine dehydrogenase dihydrouracil dehydrogenase (NADP+) 4,5-dihydrothymine: oxidoreductase DPD DHPDH dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide, phosphate) DHU dehydrogenase hydropyrimidine dehydrogenase dihydropyrimidine dehydrogenase (NADP+)
== Further reading == Hofmeister F. (1888) Arch. Exptl. Pathol. Pharmakol., 24, 247. Zhang, Y; Cremer, P (December 2006). "Interactions between macromolecules and ions: The Hofmeister series". Current Opinion in Chemical Biology. 10 (6): 658–63. doi:10.1016/j.cbpa.2006.09.020. PMID 17035073. Zhou, Huan-Xiang (October 2005). "Interactions of macromolecules with salt ions: an electrostatic theory for the Hofmeister effect". Proteins: Structure, Function, and Bioinformatics. 61 (1): 69–78. doi:10.1002/prot.20500. PMID 16044460. S2CID 4996928. Tanford C and Reynolds J. (2001) Nature's robots: a history of proteins, Oxford University Press. ISBN 0-19-850466-7 Creighton TE. (1993) Proteins, 2nd ed., W. H. Freeman. ISBN 0-7167-2317-4 Jencks WP. (1969) Catalysis in Chemistry and Enzymology, Dover republication (1987). ISBN 0-486-65460-5 Collins, KD.; Washabaugh, MW. (1985). "The Hofmeister effect and the behaviour of water at interfaces". Q Rev Biophys. 18 (4): 323–422. doi:10.1017/s0033583500005369. PMID 3916340. John Leo, Abernethy (1967). "Franz Hofmeister - The impact of his life and research on chemistry". Journal of Chemical Education. 44 (3): 177–80. Bibcode:1967JChEd..44..177A. doi:10.1021/ed044p177. PMID 5343300.
Sources: en.wikipedia.org
High Voltage Engineering Corporation (HVEC) was an American manufacturer of particle accelerators and one of the first venture capital-backed startups. HVEC originated at MIT, where physicist Robert Van de Graaff invented a high-voltage electrostatic particle accelerator and his colleague John Trump miniaturized it for cancer radiotherapy. In 1946, Trump organized a company to manufacture these machines, recruiting Van de Graaff and Denis Robinson as co-founders. Production began in a Cambridge automobile garage. The company's early medical devices gave way to large research accelerators after the Sputnik crisis increased governments' investments in nuclear physics. For two decades, HVEC accelerators were the dominant platform for nuclear physics; in the 1970s, nearly 70 percent of experimental papers relied on HVEC machines. The company built 471 accelerators between 1946 and 1981. They were installed at hospitals, universities, and national laboratories in 30 countries, and some remain in active research use. Using these instruments, HVEC subsidiaries introduced new uses of accelerator beams. Ion Physics Corporation demonstrated that ion implantation could precisely control transistor characteristics, a technique now essential to integrated circuit fabrication. Electronized Chemicals Corporation developed methods to crosslink plastics with electron beams, producing the heat-shrink tubing now ubiquitous in electrical wiring. HVEC was one of the first two startups backed by the American Research & Development Corporation, the first modern venture capital fund.
Norgestrienone, sold under the brand names Ogyline, Planor, and Miniplanor, is a progestin medication which has been used in birth control pills, sometimes in combination with ethinylestradiol. It was developed by Roussel Uclaf and has been registered for use only in France. Under the brand name Planor, it has been marketed in France as 2 mg norgestrienone and 50 μg ethinylestradiol tablets. It is taken by mouth. Norgestrienone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has some androgenic activity. Norgestrienone was first described in the literature in 1965. It is sometimes referred to as a "second-generation" progestin. Norgestrienone is no longer available.
==== Men's Euro 2024 qualification ==== 27 March – Ireland 0–1 France. 16 June – Greece 2–1 Ireland. During the match in Athens, Greek supporters were asked repeatedly over the public address system to stop shining laser beams at the Irish footballers. 19 June – Ireland 3–0 Gibraltar. 7 September – France 2–0 Ireland. 10 September – Ireland 1–2 Netherlands. 13 October – Ireland 0–2 Greece. 16 October – Gibraltar 0–4 Ireland. 18 November – Netherlands 1–0 Ireland.
== Hazards == Silica gel is non-toxic, and non-reactive and stable with ordinary usage. It will react with hydrogen fluoride, fluorine, oxygen difluoride, chlorine trifluoride, strong acids, strong bases, and oxidizers. Silica gel is irritating to the respiratory tract and may cause irritation of the digestive tract. Dust from the beads may cause irritation to the skin and eyes, so precautions should be taken. Crystalline silica dust can cause silicosis, but synthetic amorphous silica gel is indurated, so it does not cause silicosis. Additional hazards may occur when doped with a humidity indicator.
Sources: en.wikipedia.org
Back pressure (or backpressure) is the term for a resistance to the desired flow of fluid through pipes. Obstructions or tight bends create backpressure via friction loss and pressure drop. In distributed systems in particular event-driven architecture, back pressure is a technique to regulate flow of data, ensuring that components do not become overwhelmed.
The West Coast exhibition site opened on 22 June 2006 at the Tropicana Resort and Casino Las Vegas. As of June 2009, BODIES... The Exhibition is showing at the Ambassador Theatre in Dublin, Ireland. The exhibition was in Istanbul, Turkey, until the end of March 2011. Plastination galleries are offered in several college medical schools, including the University of Michigan (which Michigan Daily reported possessed the United States' largest such lab in 2007), Vienna University, and the JSS Medical Collegem Gunther von Hagens maintains a permanent exhibition of plastinates and plastination at the Plastinarium in Guben, Germany.
Newsom came under attack from the San Francisco Democratic Party in 2009 for his failure to implement the City of San Francisco's sanctuary city rule, under which the city was to not assist U.S. Immigration and Customs Enforcement. The same year, Newsom received the Leadership for Healthy Communities Award, along with Mayor Michael Bloomberg of New York City and three other public officials, for his commitment to making healthful food and physical activity options more accessible to children and families. He hosted the Urban-Rural Roundtable in 2008 to explore ways to promote regional food development and increased access to healthy, affordable food. Newsom secured $8 million in federal and local funds for the Better Streets program, which ensures that public health perspectives are fully integrated into urban planning processes. He signed a menu-labeling bill into law, requiring that chain restaurants print nutrition information on their menus. Newsom was named "America's Most Social Mayor" in 2010 by Same Point, based on analysis of the social media profiles of mayors of the 100 largest U.S. cities.
== Proteolysis and diseases == Abnormal proteolytic activity is associated with many diseases. In pancreatitis, leakage of proteases and their premature activation in the pancreas results in the self-digestion of the pancreas. People with diabetes mellitus may have increased lysosomal activity and the degradation of some proteins can increase significantly. Chronic inflammatory diseases such as rheumatoid arthritis may involve the release of lysosomal enzymes into extracellular space that break down surrounding tissues. Abnormal proteolysis may result in age-related neurological diseases such as Alzheimer's disease due to the generation and ineffective removal of peptides that aggregate in cells. Proteases may be regulated by antiproteases or protease inhibitors, and imbalance between proteases and antiproteases can result in diseases, for example, in the destruction of lung tissues in emphysema brought on by smoking tobacco. Smoking is thought to increase the neutrophils and macrophages in the lung which release excessive amount of proteolytic enzymes such as elastase, such that they can no longer be inhibited by serpins such as α1-antitrypsin, thereby resulting in the breaking down of connective tissues in the lung. Other proteases and their inhibitors may also be involved in this disease, for example matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Other diseases linked to aberrant proteolysis include muscular dystrophy, degenerative skin disorders, respiratory and gastrointestinal diseases, and malignancy.
Some cultures have long celebrated and even worshipped the vulva. During the Uruk period (c. 4000–3100 BC), the ancient Sumerians regarded the vulva as sacred and a vast number of Sumerian poems praising the vulva of Inanna, the goddess of love, sex, and fertility, have survived. In Sumerian religion, the goddess Ninimma is the divine personification of the vulva. Vaginal fluid is always described in Sumerian texts as tasting "sweet" and, in a Sumerian bridal hymn, a young maiden rejoices that her vulva has grown hair. Clay models of vulvas were discovered in the temple of Inanna at Ashur. Some major Hindu traditions such as Shaktism, a goddess-centered tradition, revere the vulva and vagina under the name yoni. The goddess as Devi is worshipped as the supreme deity. The yoni is a representation of the female deity and is found in many temples as a focus for prayer and offerings. It is also represented symbolically as a mudra in spiritual practices, including yoga. Sheela na gigs are figurative carvings of naked women displaying an exaggerated vulva. They are found in ancient and medieval European contexts. They are displayed on many churches, but their origin and significance is debatable. A main line of thinking is that they were used to ward off evil spirits. Another view is that the sheela na gig was a divine assistant in childbirth. Starr Goode explores the image and possible meanings of the Sheela na gig and Baubo images in particular, but writes also about the recurring image worldwide.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.